Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. reported revenue of $14.34B for the fiscal year ended Dec 31, 2025, up 1.0% from $14.20B the year before. Net income was $4.50B, a net margin of 31.4% (prior year: $4.41B). At the end of that fiscal year the company reported total assets of $40.56B and shareholders' equity of $31.26B.
Revenue
$14.34B
+1.0% vs prior year
Net income
$4.50B
Net margin 31.4%
Diluted EPS
$41.48
USD per share
Total assets
$40.56B
At Dec 31, 2025
Equity
$31.26B
At Dec 31, 2025
Shares outstanding
94M
As of Jul 13, 2012
Explore Regeneron Pharmaceuticals, Inc.'s filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Oct 30, 2026
- 10-QFiled Jul 30, 2026
- 10-QFiled Apr 29, 2026
- 10-KFiled Feb 4, 2026
- 10-QFiled Oct 28, 2025
- 10-QFiled Aug 1, 2025
Source: SEC EDGAR XBRL company facts for CIK 872589 (raw data). Most recent filing in this dataset: 10-Q filed Oct 30, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.